FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Ron van Schaik

Research Profile

Physiology

Genotype

Chemicals & Drugs

Genes & Molecular Sequences

Concepts & Ideas

Co-author Network

Publications

TOP 3
Rachida Bouamar; Johannes W de Fijter; Dennis A Hesselink; Dirk R J Kuypers; Ilse P van der Heiden; Ron van Schaik; Willem Weimar; Teun van Gelder
Mycophenolic acid-related diarrhea is not associated with polymorphisms in SLCO1B nor with ABCB1 in renal transplant recipients.
Laure Elens; Vincent Haufroid; Dennis A Hesselink; Ilse P van der Heiden; Teun van Gelder; Rachida Bouamar; Ron van Schaik
A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
Natella Y Rakhmanina; Steven J Soldin; Heather Gordish-Dressman; Michael N Neely; Ron van Schaik; Keetra D Williams; John N van den Anker
CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Ron van Schaik (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Rachida Bouamar; Johannes W de Fijter; Dennis A Hesselink; Dirk R J Kuypers; Ilse P van der Heiden; Ron van Schaik; Willem Weimar; Teun van Gelder
Mycophenolic acid-related diarrhea is not associated with polymorphisms in SLCO1B nor with ABCB1 in renal transplant recipients.
Pharmacogenetics and genomics 2012;22(6):399-407.
2011: Laure Elens; Vincent Haufroid; Dennis A Hesselink; Ilse P van der Heiden; Teun van Gelder; Rachida Bouamar; Ron van Schaik
A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
Clinical chemistry 2011;57(11):1574-83.
2011: Natella Y Rakhmanina; Steven J Soldin; Heather Gordish-Dressman; Michael N Neely; Ron van Schaik; Keetra D Williams; John N van den Anker
CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.
Therapeutic drug monitoring 2011;33(4):417-24.
2010: Wendy Deenik; Bronno van der Holt; Jeroen J W M Janssen; Isabel W T Chu; Peter J M Valk; Gert Ossenkoppele; Ilse P van der Heiden; Pieter Sonneveld; Ron van Schaik; Jan J Cornelissen
Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib.
Blood 2010;116(26):6144-5; author reply 6145-6.
2010: Claire Siemes; Loes E Visser; Frank de Jong; Jan-Willem W Coebergh; André G Uitterlinden; Albert Hofman; Bruno H Ch Stricker; Ron van Schaik
Cytochrome P450 3A gene variation, steroid hormone serum levels and prostate cancer--The Rotterdam Study.
Steroids 2010;75(12):1024-32.
2010: Chris H Bangma; Ron van Schaik; Bert G Blijenberg; Monique J Roobol; Hans Lilja; Ulf-Håkan Stenman
On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
European journal of cancer (Oxford, England : 1990) 2010;46(17):3109-19.
2010: L A Lammers; Ron H J Mathijssen; Teun van Gelder; M J Bijl; A-J M de Graan; Caroline Seynaeve; M A van Fessem; E M Berns; Arnold G Vulto; Ron van Schaik
The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer.
British journal of cancer 2010;103(6):765-71.
2010: Olivier Gensburger; Ron van Schaik; Nicolas Picard; Yannick Le Meur; Annick Rousseau; Jean-Baptiste Woillard; Teun van Gelder; Pierre Marquet
Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil.
Pharmacogenetics and genomics 2010;20(9):537-43.
2010: Natella Y Rakhmanina; John N van den Anker; Steven J Soldin; Ron van Schaik; Nick Mordwinkin; Michael N Neely
Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents?
Therapeutic drug monitoring 2010;32(3):273-81.
2010: P W Schenk; M van Vliet; Ron A A Mathot; Teun van Gelder; Arnold G Vulto; M A C van Fessem; S Verploegh-Van Rij; Jan Lindemans; Jan A Bruijn; Ron van Schaik
The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients.
The pharmacogenomics journal 2010;10(3):219-25.
2010: A Hartman; Ron van Schaik; Ilse P van der Heiden; M J C Broekhuis; M Meier; Monique L den Boer; Rob Pieters
Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia.
Leukemia research 2010;34(2):154-9.
2010: Jessica van der Bol; Floris A de Jong; Ron van Schaik; Alex Sparreboom; Marianne A van Fessem; Fleur E van de Geijn; P L A van Daele; Jaap Verweij; Stefan Sleijfer; Ron H J Mathijssen
Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia.
The oncologist 2010;15(10):1063-72.
2010: Matthijs L Becker; Loes E Visser; Ron van Schaik; Albert Hofman; André G Uitterlinden; Bruno H Ch Stricker
Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response.
Pharmacogenetics and genomics 2010;20(1):38-44.
2010: Matthijs L Becker; Loes E Visser; Ron van Schaik; Albert Hofman; André G Uitterlinden; Bruno H Ch Stricker
Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy.
Pharmacoepidemiology and drug safety 2010;19(1):75-81.
2009: Matthijs L Becker; Loes E Visser; Ron van Schaik; Albert Hofman; André G Uitterlinden; Bruno H Ch Stricker
Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in males.
Pharmacogenomics 2009;10(11):1743-51.
2009: Bart J B Bliek; Ron van Schaik; Ilse P van der Heiden; Fakhredin A Sayed-Tabatabaei; Cock M van Duijn; Eric A P Steegers; Régine P M Steegers-Theunissen
Maternal medication use, carriership of the ABCB1 3435C > T polymorphism and the risk of a child with cleft lip with or without cleft palate.
American journal of medical genetics. Part A 2009;149A(10):2088-92.
2009: Ron van Schaik; M van Agteren; Johan W de Fijter; Arndt Hartmann; J Schmidt; K Budde; D Kuypers; Y Le Meur; Marloes van der Werf; Richard D Mamelok; Teun van Gelder
UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients.
Clinical pharmacology and therapeutics 2009;86(3):319-27.
2009: Sonja Kwadijk-de Gijsel; Monique J Bijl; Loes E Visser; Ron van Schaik; Albert Hofman; Arnold G Vulto; Teun van Gelder; Bruno H Ch Stricker
Variation in the CYP2D6 gene is associated with a lower serum sodium concentration in patients on antidepressants.
British journal of clinical pharmacology 2009;68(2):221-5.
2009: Matthijs L Becker; Loes E Visser; Ron van Schaik; Albert Hofman; André G Uitterlinden; B H C Stricker
Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus.
The pharmacogenomics journal 2009;9(4):242-7.
2009: Adrian Kruit; Madeleine M Tilanus-Linthorst; Joke G Boonstra; Ron van Schaik; Jan C Grutters; Jules M M van den Bosch; Henk Ruven
MUC1 568 A/G genotype-dependent cancer antigen 15-3 levels in breast cancer patients.
Clinical biochemistry 2009;42(7-8):662-5.
2009: Claire Siemes; M Eijgelsheim; Jeanne P Dieleman; Ron van Schaik; André G Uitterlinden; C.M. Duijn; Albert Hofman; J W W Coebergh; B H Ch Stricker; Loes E Visser
No modification of the beneficial effect of NSAIDs on colorectal cancer by CYP2C9 genotype.
The Netherlands journal of medicine 2009;67(4):134-41.
2009: Monique J Bijl; Hendrika J Luijendijk; Julia F van den Berg; Loes E Visser; Ron van Schaik; Albert Hofman; Arnold G Vulto; Teun van Gelder; Henning Tiemeier; Bruno H Ch Stricker
Association between the CYP2D6*4 polymorphism and depression or anxiety in the elderly.
Pharmacogenomics 2009;10(4):541-7.
2009: M Teichert; Ron van Schaik; Albert Hofman; André G Uitterlinden; Peter A G M de Smet; B H C H Stricker; Loes E Visser
Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period.
Clinical pharmacology and therapeutics 2009;85(4):379-86.
2009: Matthijs van Luin; Annemarie Brouwer; Andre van der Ven; Wiel de Lange; Ron van Schaik; David Burger
Efavirenz dose reduction to 200 mg once daily in a patient treated with rifampicin.
AIDS (London, England) 2009;23(6):742-4.
2009: Matthijs L Becker; Loes E Visser; Ron van Schaik; Albert Hofman; André G Uitterlinden; Bruno H Ch Stricker
Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study.
Diabetes 2009;58(3):745-9.
2009: M J Bijl; L E Visser; Ron van Schaik; J A Kors; J C M Witteman; Albert Hofman; A G Vulto; T van Gelder; B H Ch Stricker
Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users.
Clinical pharmacology and therapeutics 2009;85(1):45-50.
2008: F H Jansen; Monique J Roobol; Chris H Bangma; Ron van Schaik
Clinical impact of new prostate-specific antigen WHO standardization on biopsy rates and cancer detection.
Clinical chemistry 2008;54(12):1999-2006.
2008: Madelon van Agteren; Victor W Armstrong; Ron van Schaik; Hans de Fijter; Anders Hartmann; Martin Zeier; Klemens Budde; Dirk Kuypers; Przemyslav Pisarski; Yann Le Meur; Marloes van der Werf; Richard D Mamelok; Michael Oellerich; Teun van Gelder
AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism.
Therapeutic drug monitoring 2008;30(4):439-44.
2008: Dennis A Hesselink; Ron van Schaik; Jeroen Nauta; Teun van Gelder
A drug transporter for all ages? ABCB1 and the developmental pharmacogenetics of cyclosporine.
Pharmacogenomics 2008;9(6):783-9.
2008: Ron van Schaik
CYP450 pharmacogenetics for personalizing cancer therapy.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2008;11(3):77-98.
2008: Karel Allegaert; Ron van Schaik; Steve Vermeersch; Rene Verbesselt; Veerle Cossey; Christine Vanhole; Marianne van Fessem; Jan de Hoon; John N van den Anker
Postmenstrual age and CYP2D6 polymorphisms determine tramadol o-demethylation in critically ill neonates and infants.
Pediatric research 2008;63(6):674-9.
2008: P W Schenk; M A C van Fessem; S Verploegh-Van Rij; Ron A A Mathot; Teun van Gelder; Arnold G Vulto; M van Vliet; Jan Lindemans; Jan A Bruijn; Ron van Schaik
Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients.
Molecular psychiatry 2008;13(6):597-605.
2008: Nicole G Hunfeld; Ron A Mathot; Daan J Touw; Ron van Schaik; Paul G Mulder; Paul F Franck; Ernst J Kuipers; William P Geus
Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians.
British journal of clinical pharmacology 2008;65(5):752-60.
2008: Johannes H van der Kolk; Johannes P T M van Leeuwen; A J M van den Belt; Ron van Schaik; W Schaftenaar
Subclinical hypocalcaemia in captive Asian elephants (Elephas maximus).
The Veterinary record 2008;162(15):475-9.
2008: Dennis A Hesselink; Ron van Schaik; Madelon van Agteren; Johannes W de Fijter; Anders Hartmann; Martin Zeier; Klemens Budde; Dirk R J Kuypers; Przemyslav Pisarski; Yann Le Meur; Richard D Mamelok; Teun van Gelder
CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients.
Pharmacogenetics and genomics 2008;18(4):339-48.
2008: Albert-Jan L H J Aarnoudse; Jeanne P Dieleman; Loes E Visser; Pascal P Arp; Ilse P van der Heiden; Ron van Schaik; Mariam Molokhia; Albert Hofman; André G Uitterlinden; Bruno H Ch Stricker
Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration.
Pharmacogenetics and genomics 2008;18(4):299-305.
2008: Karel Allegaert; John N van den Anker; Jan de Hoon; Ron van Schaik; Anne Debeer; Dick Tibboel; Gunnar Naulaers; B J Anderson
Covariates of tramadol disposition in the first months of life.
British journal of anaesthesia 2008;100(4):525-32.
2008: M Teichert; Loes E Visser; Ron van Schaik; Albert Hofman; André G Uitterlinden; P A G M De Smet; Jacqueline C M Witteman; B H Ch Stricker
Vitamin K epoxide reductase complex subunit 1 (VKORC1) polymorphism and aortic calcification: the Rotterdam Study.
Arteriosclerosis, thrombosis, and vascular biology 2008;28(4):771-6.
2008: Monique J Bijl; Loes E Visser; Albert Hofman; Arnold G Vulto; Teun van Gelder; Bruno H Ch Stricker; Ron van Schaik
Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants.
British journal of clinical pharmacology 2008;65(4):558-64.
2008: Deepika S Darbari; Ron van Schaik; Edmund V Capparelli; Sohail Rana; Robert McCarter; John van den Anker
UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease.
American journal of hematology 2008;83(3):200-2.
2008: Matthijs L Becker; Loes E Visser; Paul H Trienekens; Albert Hofman; Ron van Schaik; B H Ch Stricker
Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.
Clinical pharmacology and therapeutics 2008;83(2):288-92.
2007: Mark-David Levin; Jan G Den Hollander; Bronno van der Holt; Bart J A Rijnders; Martin van Vliet; Pieter Sonneveld; Ron van Schaik
Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms.
The Journal of antimicrobial chemotherapy 2007;60(5):1104-7.
2007: Maxime T M Kummeling; Bas W D de Jong; Charlie Laffeber; dirk kok; Paul C M S Verhagen; Geert J L H van Leenders; Ron van Schaik; Christiaan S van Woerden; Anja Verhulst; Carl F Verkoelen
Tubular and interstitial nephrocalcinosis.
The Journal of urology 2007;178(3 Pt 1):1097-103.
2007: Frederike K Engels; Walter J Loos; Ron A A Mathot; Ron van Schaik; Jaap Verweij
Influence of ketoconazole on the fecal and urinary disposition of docetaxel.
Cancer chemotherapy and pharmacology 2007;60(4):569-79.
2007: Elke H J Krekels; John N van den Anker; Paola Baiardi; Massimo Cella; Katharine Y Cheng; Diana M Gibb; Hannah Green; Achille Iolascon; Evelyne M Jacqz-Aigrain; Catherijne A J Knibbe; Gijs W E Santen; Ron van Schaik; Dick Tibboel; Oscar Della-Pasqua
Pharmacogenetics and paediatric drug development: issues and consequences to labelling and dosing recommendations.
Expert opinion on pharmacotherapy 2007;8(12):1787-99.
2007: Jessica van der Bol; Ron H J Mathijssen; Walter J Loos; Lena E Friberg; Ron van Schaik; M J A de Jonge; A S T Planting; Jaap Verweij; Alex Sparreboom; Floris A de Jong
Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(19):2719-26.
2007: Loes E Visser; Ron van Schaik; Alexander H Jan Danser; Albert Hofman; Jacqueline C M Witteman; C.M. Duijn; André G Uitterlinden; Huibert A P Pols; Bruno H Ch Stricker
The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9.
Pharmacogenetics and genomics 2007;17(7):473-9.
2007: Mojgan Yazdanpanah; Yurii Aulchenko; Albert Hofman; Joop A M J L Janssen; Fakhredin A Sayed-Tabatabaei; Ron van Schaik; Olaf Klungel; Bruno H Ch Stricker; Huibert A P Pols; Jacqueline C M Witteman; Steven W J Lamberts; Ben A Oostra; C.M. Duijn
Effects of the renin-angiotensin system genes and salt sensitivity genes on blood pressure and atherosclerosis in the total population and patients with type 2 diabetes.
Diabetes 2007;56(7):1905-12.
2007: A Verzijl; Rogier Heide; Arnold P Oranje; Ron van Schaik
C-kit Asp-816-Val mutation analysis in patients with mastocytosis.
Dermatology (Basel, Switzerland) 2007;214(1):15-20.
2007: Su-Jun Lee; Ilse P van der Heiden; Joyce A Goldstein; Ron van Schaik
A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression system.
Drug metabolism and disposition: the biological fate of chemicals 2007;35(1):67-71.
2006: Wenxia Chai; Yvonne M Hoedemaekers; Ron van Schaik; Marianne van Fessem; Ingrid M Garrelds; Jasper J Saris; Dennis Dooijes; Folkert J Ten Cate; Marcel M J Kofflard; Alexander Hessel Jan Danser
Cardiac aldosterone in subjects with hypertrophic cardiomyopathy.
Journal of the renin-angiotensin-aldosterone system : JRAAS 2006;7(4):225-30.
2006: Mariska Y M Peeters; Sandra A Prins; Catherijne A J Knibbe; Joost DeJongh; Ron A A Mathôt; Celesta Warris; Ron van Schaik; Dick Tibboel; Meindert Danhof
Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery.
Anesthesiology 2006;105(6):1135-46.
2006: Jan Hofland; Marianna A Timmerman; Wouter W de Herder; Ron van Schaik; Ronald R de Krijger; Frank de Jong
Expression of activin and inhibin subunits, receptors and binding proteins in human adrenocortical neoplasms.
Clinical endocrinology 2006;65(6):792-9.
2006: Bronno van der Holt; Marry M van den Heuvel-Eibrink; Ron van Schaik; Ilse P van der Heiden; Erik A C Wiemer; P J M Vossebeld; Bob Löwenberg; Pieter Sonneveld
ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients.
Clinical pharmacology and therapeutics 2006;80(5):427-39.
2006: Albert L H J Aarnoudse; Ron van Schaik; Jeanne P Dieleman; Mariam Molokhia; Melanie M van Riemsdijk; Robert J Ligthelm; David Overbosch; Ilse P van der Heiden; Bruno H Ch Stricker
MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine.
Clinical pharmacology and therapeutics 2006;80(4):367-74.
2006: Floris A de Jong; Diederik F S Kehrer; Ron H J Mathijssen; Geert-Jan Creemers; Peter de Bruijn; Ron van Schaik; A S T Planting; Ate van der Gaast; Ferry A L M Eskens; Jos Th P Janssen; Jan B Ruit; Jaap Verweij; Alex Sparreboom; M J A de Jonge
Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
The oncologist 2006;11(8):944-54.
2006: Erin R Gardner; Herman Burger; Ron van Schaik; Allan T van Oosterom; Ernst A de Bruijn; Gunther Guetens; Hans Prenen; Floris A de Jong; Sharyn D Baker; Susan E Bates; William D Figg; Jaap Verweij; Alex Sparreboom; Kees Nooter
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib.
Clinical pharmacology and therapeutics 2006;80(2):192-201.
2006: Judith M de Bont; Monique L den Boer; Roel E Reddingius; Jaap Jansen; Monique Passier; Ron van Schaik; Johan M Kros; Peter A E Sillevis Smitt; Theo H Luider; Rob Pieters
Identification of apolipoprotein A-II in cerebrospinal fluid of pediatric brain tumor patients by protein expression profiling.
Clinical chemistry 2006;52(8):1501-9.
2006: Frederike K Engels; Ron A A Mathot; Walter J Loos; Ron van Schaik; Jaap Verweij
Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.
Cancer biology & therapy 2006;5(7):833-9.
2006: A van der Padt; Ron van Schaik; Pieter Sonneveld
Acute dystonic reaction to metoclopramide in patients carrying homozygous cytochrome P450 2D6 genetic polymorphisms.
The Netherlands journal of medicine 2006;64(5):160-2.
2006: Mariska Y M Peeters; Sandra A Prins; Catherijne A J Knibbe; Joost DeJongh; Ron van Schaik; Monique van Dijk; Ilse P van der Heiden; Dick Tibboel; Meindert Danhof
Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery.
Anesthesiology 2006;104(3):466-74.
2006: Ron H J Mathijssen; Ron van Schaik
Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment.
European journal of cancer (Oxford, England : 1990) 2006;42(2):141-8.
2005: Ron van Schaik
Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.
Investigational new drugs 2005;23(6):513-22.
2005: Erin R Lepper; Sharyn D Baker; Matthew G Permenter; Nicole Ries; Ron van Schaik; Paul W Schenk; Douglas K Price; Danielle Ahn; Nicola F Smith; George Cusatis; Roxann G Ingersoll; Susan E Bates; Ron H J Mathijssen; Jaap Verweij; William D Figg; Alex Sparreboom
Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(20):7398-404.
2005: pauline smit; Ron van Schaik; Marloes van der Werf; Annewieke W van den Beld; Jan W Koper; Jan Lindemans; Huibert A P Pols; Albert O Brinkmann; Frank de Jong; Steven W J Lamberts
A common polymorphism in the CYP3A7 gene is associated with a nearly 50% reduction in serum dehydroepiandrosterone sulfate levels.
The Journal of clinical endocrinology and metabolism 2005;90(9):5313-6.
2005: Dennis A Hesselink; Teun van Gelder; Ron van Schaik
The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression?
Pharmacogenomics 2005;6(4):323-37.
2005: Loes E Visser; Ron van Schaik; Martin van Vliet; Paul H Trienekens; Peter A G M de Smet; Arnold G Vulto; Albert Hofman; C.M. Duijn; Bruno H Ch Stricker
Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants.
Clinical pharmacology and therapeutics 2005;77(6):479-85.
2005: Otto Soepenberg; Herlinde Dumez; Jaap Verweij; Floris A de Jong; M J A de Jonge; José Thomas; Ferry A L M Eskens; Ron van Schaik; Johan Selleslach; Judith ter Steeg; Patricia Lefebvre; Sylvie Assadourian; Ger-Jan Sanderink; Alex Sparreboom; Allan T van Oosterom
Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(4):1504-11.
2004: Sharyn D Baker; Ron van Schaik; Laurent P Rivory; Albert J ten Tije; Kimberly Dinh; Wilfried J Graveland; Paul W Schenk; Kellie A Charles; Stephen J Clarke; Michael A Carducci; William P McGuire; Fitzroy W Dawkins; Hans Gelderblom; Jaap Verweij; Alex Sparreboom
Factors affecting cytochrome P-450 3A activity in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(24):8341-50.
2004: Dennis A Hesselink; Teun van Gelder; Ron van Schaik; Aggie H M M Balk; Ilse P van der Heiden; Teus Van Dam; Marloes van der Werf; Willem Weimar; Ron A A Mathot
Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes.
Clinical pharmacology and therapeutics 2004;76(6):545-56.
2004: Ron H J Mathijssen; Floris A de Jong; Ron van Schaik; Erin R Lepper; Lena E Friberg; Trinet Rietveld; Peter de Bruijn; Wilfried J Graveland; William D Figg; Jaap Verweij; Alex Sparreboom
Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
Journal of the National Cancer Institute 2004;96(21):1585-92.
2004: Joop A M J L Janssen; Mark F Wildhagen; K Ito; Bert G Blijenberg; Ron van Schaik; Monique J Roobol; Huibert A P Pols; Steven W J Lamberts; F H Schröder
Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval.
The Journal of clinical endocrinology and metabolism 2004;89(9):4391-6.
2004: Teun van Gelder; Dennis A Hesselink; Reinier M van Hest; Ron A A Mathôt; Ron van Schaik
Pharmacogenetics in immunosuppressive therapy: the best thing since TDM?
Therapeutic drug monitoring 2004;26(4):343-6.
2004: Loes E Visser; Ron van Schaik; Martin van Vliet; Paul H Trienekens; Peter A G M de Smet; Arnold G Vulto; Albert Hofman; C.M. Duijn; Bruno H Ch Stricker
The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.
Thrombosis and haemostasis 2004;92(1):61-6.
2004: Ron van Schaik
Implications of cytochrome P450 genetic polymorphisms on the toxicity of antitumor agents.
Therapeutic drug monitoring 2004;26(2):236-40.
2004: Loes E Visser; Martin van Vliet; Ron van Schaik; A A Harrie Kasbergen; Peter A G M de Smet; Arnold G Vulto; Albert Hofman; C.M. Duijn; Bruno H Ch Stricker
The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.
Pharmacogenetics 2004;14(1):27-33.
2004: Ilse P van der Heiden; Marloes van der Werf; Jan Lindemans; Ron van Schaik
Sequencing: not always the "gold standard".
Clinical chemistry 2004;50(1):248-9.
2003: Dennis A Hesselink; Ron van Schaik; Ilse P van der Heiden; Marloes van der Werf; Peter J H Smak Gregoor; Jan Lindemans; Willem Weimar; Teun van Gelder
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.
Clinical pharmacology and therapeutics 2003;74(3):245-54.
2002: Ron van Schaik; Ilse P van der Heiden; John N van den Anker; Jan Lindemans
CYP3A5 variant allele frequencies in Dutch Caucasians.
Clinical chemistry 2002;48(10):1668-71.
2001: Ron van Schaik; Saskia N de Wildt; R Brosens; M van Fessem; John N van den Anker; Jan Lindemans
The CYP3A4*3 allele: is it really rare?
Clinical chemistry 2001;47(6):1104-6.
2001: Hannsjörg Baum; T Bertsch; J Bohner; K W von Pap; Torsten Hoff; B Wilke; Norbert Katz; Hilmar Luthe; H Luz; Dorothea Nagel; C Niederhauser; Ron van Schaik; C Aschenneller; I Schul; Rainer Zerback
Detection limit, cut-off and specificity of an improved rapid assay for cardiac troponin T.
Clinical laboratory 2001;47(11-12):549-54.
2000: Ron van Schaik; Saskia N de Wildt; N M van Iperen; A G Uitterlinden; John N van den Anker; Jan Lindemans
CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians.
Clinical chemistry 2000;46(11):1834-6.
2000: Ron van Schaik; CD Wierikx; Marianna A Timmerman; Monique H Oomen; Wytske M Van Weerden; Theo Van der Kwast; Gert J van Steenbrugge; Frank de Jong
Variations in activin receptor, inhibin/activin subunit and follistatin mRNAs in human prostate tumour tissues.
British journal of cancer 2000;82(1):112-7.
1999: Marten A Engelse; Jolanda M Neele; Tanja A E Van Achterberg; Benien E van Aken; Ron van Schaik; Hans Pannekoek; Carlie J M de Vries
Human activin-A is expressed in the atherosclerotic lesion and promotes the contractile phenotype of smooth muscle cells.
Circulation research 1999;85(10):931-9.
1999: Pieter H Griffioen; L Zwang; Ron van Schaik; H Engel; Jan Lindemans; Christa Cobbaert
Optimization of apolipoprotein(a) genotyping with pulsed field gel electrophoresis.
Clinical chemistry 1999;45(6 Pt 1):771-6.
1998: Jan Th J Uilenbroek; Alexandra L L Durlinger; M Tebar; Piet Kramer; Ron van Schaik; CD Wierikx; Frank de Jong
Temporal changes in inhibin subunit mRNAs during atresia of preovulatory follicles in the rat.
The Journal of endocrinology 1998;159(2):331-40.
1998: AA Caricasole; Ron van Schaik; Laura M Zeinstra; CD Wierikx; Ruud van Gurp; M van den Pol; Leendert H J Looijenga; J Wolter Oosterhuis; M F Pera; A Ward; D de Bruijn; Piet Kramer; Frank de Jong; AJ van den Eijnden-van Raaij
Human growth-differentiation factor 3 (hGDF3): developmental regulation in human teratocarcinoma cell lines and expression in primary testicular germ cell tumours.
Oncogene 1998;16(1):95-103.
1997: M Tébar; Jan Th J Uilenbroek; Piet Kramer; Ron van Schaik; CD Wierikx; A Ruiz; Frank de Jong; José E Sánchez-Criado
Effects of progesterone on the secondary surge of follicle-stimulating hormone in the rat.
Biology of reproduction 1997;57(1):77-84.
1997: John Martens; J P de Winter; Marianna A Timmerman; Anke McLuskey; Ron van Schaik; Axel P N Themmen; Frank de Jong
Inhibin interferes with activin signaling at the level of the activin receptor complex in Chinese hamster ovary cells.
Endocrinology 1997;138(7):2928-36.
1997: Ron van Schaik; CD Wierikx; Leendert H J Looijenga; J Wolter Oosterhuis; Frank de Jong
Human testicular germ cell tumours express inhibin subunits, activin receptors and follistatin mRNAs.
British journal of cancer 1997;76(9):1191-8.
1996: Timo Tuuri; M Erämaa; Ron van Schaik; Olli Ritvos
Differential regulation of inhibin/activin alpha- and beta A-subunit and follistin mRNAs by cyclic AMP and phorbol ester in cultured human granulosa-luteal cells.
Molecular and cellular endocrinology 1996;121(1):1-10.
1993: Ron van Schaik; N M Verhoeven; F W Neijs; A J Aarsman; H Van den Bosch
Cloning of the cDNA coding for 14 kDa group II phospholipase A2 from rat liver.
Biochimica et biophysica acta 1993;1169(1):1-11.
1993: Ron van Schaik; C D van den Koeduk; F W Neijs; A J Aarsman; H van den Bosch
Monoclonal antibodies against rat liver mitochondrial phospholipase A2: epitope analysis and application in western blotting.
The International journal of biochemistry 1993;25(3):433-9.
1990: H van den Bosch; A J Aarsman; Ron van Schaik; C G Schalkwijk; F W Neijs; A Sturk
Structural and enzymological properties of cellular phospholipases A2.
Biochemical Society transactions 1990;18(5):781-5.